Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005659700
Thu, 23.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 23 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) closed FY 2022 with sales of 222.3 million EUR. Net income for the year rose by around 20% compared to the previous year's figure adjusted for special effects and reached 29.3 million EUR, which corresponds to earnings per share of 1.41 EUR. Based on these figures, Executiv [ … ]
Fri, 03.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 3 March 2023. Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetium-177), an active pharmaceutical ingredient and received DMF registration number 038043.
[ … ]
Fri, 03.03.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 3 March 2023. Eckert & Ziegler (ISIN DE0005659700, SDAX) has successfully submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration for lutetium (177Lu) chloride solution (containing no-carrier-added radioisotope Lutetium-177), an active pharmaceutical ingredient and received DMF registration number 038043.
[ … ]
Wed, 01.02.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 01.02.2023. The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting. It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical [ … ]
Wed, 01.02.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 01.02.2023. The Lausanne University Hospital (CHUV) has reported the initial dosing of a patient in a phase II clinical study investigating the sensitivity of PENTIXAFOR (Boclatixafotide) in a cardiovascular and inflammatory setting. It is the first time that Eckert & Ziegler’s proprietary CXCR4-compound is used in an advanced clinical [ … ]
Tue, 17.01.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 17 January 2023. According to preliminary, unaudited figures, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) is expected to achieve a Group net profit of roughly EUR 30 million and Group sales of around EUR 225 million for the 2022 financial year. The result is thus expected to be around 10% higher than the f [ … ]
Tue, 20.12.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 20.12.2022. Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX). She replaces sinologist Jutta Ludwig, who will move to the Executive Board of Eckert & Ziegler AG as Asia Repre [ … ]
Tue, 20.12.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 20.12.2022. Eckert Wagniskapital und Frühphasenfinanzierung GmbH has appointed radiation physicist Paola Eckert-Palvarini as its new representative on the Supervisory Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX). She replaces sinologist Jutta Ludwig, who will move to the Executive Board of Eckert & Ziegler AG as Asia Repre [ … ]
Mon, 19.12.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 19.12.2022. The founder and CEO of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), Dr. Andreas Eckert, today gave notice to the company that he intends to transfer from the Management to the Supervisory Board after the company’s General Shareholder Meeting in mid-2023. Before that the Supervisory Board appointed, for a period of two year [ … ]
Mon, 19.12.2022
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 19.12.2022. The founder and CEO of Eckert & Ziegler AG (ISIN DE0005659700, SDAX), Dr. Andreas Eckert, today gave notice to the company that he intends to transfer from the Management to the Supervisory Board after the company’s General Shareholder Meeting in mid-2023. Before that the Supervisory Board appointed, for a period of two year [ … ]